Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection

Abhijit A. Date, Annemarie Shibata, Emily McMullen, Krista La Bruzzo, Patrick Bruck, Michael Belshan, You Zhou, Christopher J. Destache

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The objective of this investigation was to develop and evaluate a nano-microbicide containing a combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) for HIV prophylaxis. Cellulose acetate phthalateefavirenz combination nanoparticles (CAP-EFV-NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size <100 nm, negative surface charge and encapsulation efficiency of efavirenz was >98%. CAP-EFV-NPs and CAP-EFV-NP-Gel were significantly less toxic (P < 0.01) to HeLa cells as compared to efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P <0.01) against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV prophylaxis.

Original languageEnglish (US)
Pages (from-to)416-427
Number of pages12
JournalJournal of Biomedical Nanotechnology
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

efavirenz
Nanoparticles
HIV Infections
HIV-1
Cellulose
Gels
Anti-Infective Agents
HeLa Cells
cellulose acetate phthalate
HIV Fusion Inhibitors
acetylcellulose
HIV
Anti-HIV Agents

Keywords

  • Cellulose acetate phthalate
  • Efavirenz
  • HIV prophylaxis
  • Nanoparticles
  • Pluronic
  • Thermosensitive gel

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection. / Date, Abhijit A.; Shibata, Annemarie; McMullen, Emily; La Bruzzo, Krista; Bruck, Patrick; Belshan, Michael; Zhou, You; Destache, Christopher J.

In: Journal of Biomedical Nanotechnology, Vol. 11, No. 3, 01.03.2015, p. 416-427.

Research output: Contribution to journalArticle

Date, Abhijit A. ; Shibata, Annemarie ; McMullen, Emily ; La Bruzzo, Krista ; Bruck, Patrick ; Belshan, Michael ; Zhou, You ; Destache, Christopher J. / Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection. In: Journal of Biomedical Nanotechnology. 2015 ; Vol. 11, No. 3. pp. 416-427.
@article{01e39231ac444639b3556342227ec112,
title = "Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection",
abstract = "The objective of this investigation was to develop and evaluate a nano-microbicide containing a combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) for HIV prophylaxis. Cellulose acetate phthalateefavirenz combination nanoparticles (CAP-EFV-NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size <100 nm, negative surface charge and encapsulation efficiency of efavirenz was >98{\%}. CAP-EFV-NPs and CAP-EFV-NP-Gel were significantly less toxic (P < 0.01) to HeLa cells as compared to efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P <0.01) against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV prophylaxis.",
keywords = "Cellulose acetate phthalate, Efavirenz, HIV prophylaxis, Nanoparticles, Pluronic, Thermosensitive gel",
author = "Date, {Abhijit A.} and Annemarie Shibata and Emily McMullen and {La Bruzzo}, Krista and Patrick Bruck and Michael Belshan and You Zhou and Destache, {Christopher J.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1166/jbn.2015.1942",
language = "English (US)",
volume = "11",
pages = "416--427",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "3",

}

TY - JOUR

T1 - Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection

AU - Date, Abhijit A.

AU - Shibata, Annemarie

AU - McMullen, Emily

AU - La Bruzzo, Krista

AU - Bruck, Patrick

AU - Belshan, Michael

AU - Zhou, You

AU - Destache, Christopher J.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The objective of this investigation was to develop and evaluate a nano-microbicide containing a combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) for HIV prophylaxis. Cellulose acetate phthalateefavirenz combination nanoparticles (CAP-EFV-NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size <100 nm, negative surface charge and encapsulation efficiency of efavirenz was >98%. CAP-EFV-NPs and CAP-EFV-NP-Gel were significantly less toxic (P < 0.01) to HeLa cells as compared to efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P <0.01) against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV prophylaxis.

AB - The objective of this investigation was to develop and evaluate a nano-microbicide containing a combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) for HIV prophylaxis. Cellulose acetate phthalateefavirenz combination nanoparticles (CAP-EFV-NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size <100 nm, negative surface charge and encapsulation efficiency of efavirenz was >98%. CAP-EFV-NPs and CAP-EFV-NP-Gel were significantly less toxic (P < 0.01) to HeLa cells as compared to efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P <0.01) against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV prophylaxis.

KW - Cellulose acetate phthalate

KW - Efavirenz

KW - HIV prophylaxis

KW - Nanoparticles

KW - Pluronic

KW - Thermosensitive gel

UR - http://www.scopus.com/inward/record.url?scp=84918502614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918502614&partnerID=8YFLogxK

U2 - 10.1166/jbn.2015.1942

DO - 10.1166/jbn.2015.1942

M3 - Article

C2 - 26307825

AN - SCOPUS:84918502614

VL - 11

SP - 416

EP - 427

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 3

ER -